Remus Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
What the Q4 FY26 call signalled
3 of 4 strong
The short version
Future Growth Expectations for Remus Pharmaceuticals: - Revenue Growth: Consolidated revenue grew 38% YoY in FY 2026; expected to continue strong growth driven by expanding markets. Remus Pharmaceuticals expects significant growth in both B2C and B2B segments in FY 2027.
From Remus Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
2 more points from Remus Pharmaceuticals Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Remus Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Remus Pharmaceuticals is focused on an asset-light model, primarily outsourcing manufacturing to CMOs rather than investing heavily in fixed assets.
- The company is creating infrastructure that may not be visibly asset-heavy but is critical from a brand-building perspective.
- There have been investments in R&D (~Rs. 4 crores) including bioequivalence studies and clinical trials to access markets requiring human clinical data, enabling better margins.
- The strategy is to continue without owning manufacturing assets, similar to models like Eris Pharmaceuticals before it acquired plants.
- New subsidiaries, such as Espee Global Clinical Trial Services, are expected to become operational soon, which will contribute partially to margins.
2 more points from Remus Pharmaceuticals Ltd's call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Remus Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Remus Pharmaceuticals Ltd's call on order book
Create a free account to keep reading this call
Continue your research
What Remus Pharmaceuticals's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call analysis →
- Q4 FY25 earnings call analysis →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Remus Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Remus Pharmaceuticals Ltd Q4 FY26 results?
Future Growth Expectations for Remus Pharmaceuticals: - Revenue Growth: Consolidated revenue grew 38% YoY in FY 2026; expected to continue strong growth driven by expanding markets. Remus Pharmaceuticals expects significant growth in both B2C and B2B segments in FY 2027.
What is Remus Pharmaceuticals Ltd share price analysis?
Remus Pharmaceuticals Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 31.9 with a market cap of ₹1,181 Cr. Investors should review the full earnings analysis for detailed insights.
Is Remus Pharmaceuticals Ltd planning capital expenditure?
Remus Pharmaceuticals is focused on an asset-light model, primarily outsourcing manufacturing to CMOs rather than investing heavily in fixed assets.
Keep Remus Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
